Resolution of hyphaema following intracameral injection of tenecteplase in a Stock Horse.

This research shares the use of a new-generation plasminogen activator, tenecteplase, for treating ocular traumas in horses that result in hyphaema. However, a large dose resulted in potential complications of retinopathy and keratopathy.

Introduction

• The research describes a test case where a Stock Horse suffered from an ocular trauma, resulting in hyphaema, a condition characterized by blood in the anterior chamber of the eye. This condition increases the risk of synechia (adhesion of the iris to either the cornea or lens) and formation of a fibrotic membrane, both of which can impede healing and recovery.

Solution

• To alleviate this condition, an intraocular injection of tissue plasminogen activator has been suggested. This helps expedite the clearance of blood from the eye’s anterior chamber, thereby reducing the risk of further complications.
• In this specific test case, the researchers used tenecteplase (TNK), a new-generation plasminogen activator to treat the horse’s condition. This proved successful, leading to the quick resolution of hyphaema.

Side Effects

• The trial, however, noted that an administered large dose (1 mg) of TNK might have been associated with retinopathy (damage to the retina of the eyes, which might cause vision problems) and keratopathy (diseases or abnormalities of the cornea).

Future Implications

• Despite these potentially associated conditions, tenecteplase may still be an effective treatment for equine hyphaema. The research emphasizes the need for further controlled clinical or experimental studies to more definitively ascertain the efficacy and safety profiles of this new-generation plasminogen activator.